



# MABTHERA<sup>®</sup> (RITUXIMAB)

*A comparison card to differentiate between the two formulations of MabThera<sup>®</sup> (subcutaneous and intravenous)*

**This leaflet has been produced by Roche for physicians, nurses and pharmacists for the safe and efficient use of MabThera<sup>®</sup> solution for subcutaneous injection (referred to as MabThera<sup>®</sup> SC) in patients with CLL and NHL**

# Please make sure that you select the correct MabThera® formulation

## SUBCUTANEOUS INJECTION

*For use in Non-Hodgkins Lymphoma ONLY \**

MabThera® 1400 mg solution for subcutaneous injection



Withdraw directly from the vial and administer by subcutaneous injection



Check for the specific MabThera® SC packaging characteristics before use:

1. Red labelling: 'For subcutaneous use only', 'solution for subcutaneous injection' and 'SC'
2. Pink flip-off cap

## INTRAVENOUS INFUSION

*For use in all MabThera®-approved indications*

MabThera® 100 mg concentrate for solution for infusion  
MabThera® 500 mg concentrate for solution for infusion  
For use in all MabThera-approved indications



Dilute with 0.9% NaCl or 5% glucose and administer by intravenous infusion

Check for the specific MabThera® IV packaging characteristics before use:

1. Grey labelling: 'For intravenous use only', 'solution for infusion'
2. Grey flip-off cap



Please refer to the approved package insert for further information.

Roche Products Ghana Ltd, No. Y21B Agostino Neto Road, Airport Residential Area, Accra, Ghana . P O. Box CT 2765, Cantonments, Accra, Ghana .  
Tel: +(233) 302 774752 . For adverse event reporting, please send an email to [global.irt\\_sahubtcs@roche.com](mailto:global.irt_sahubtcs@roche.com) or call +(233) 554304426.  
For product complaints, please send an email to [accra.product\\_qualitycomplaints@roche.com](mailto:accra.product_qualitycomplaints@roche.com). For Medical Information Requests, please send an email to [accra.medinfo@roche.com](mailto:accra.medinfo@roche.com)

For FDA reporting kindly send an email to :[drug.safety@fdaghana.gov.gh](mailto:drug.safety@fdaghana.gov.gh)